Hui-Lee Wong

Hui-Lee Wong

Auto-generated profile, based on publicly available information

Hui-Lee Wong

US Food and Drug Administration

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2010 in AIDS
Verified
Journal Article
Closed access
HWHui-Lee Wong
Hui-Lee Wong
EBElizabeth C Breen
Elizabeth C Breen
RPRuth M Pfeiffer
Ruth M Pfeiffer
BABrahim Aissani
Brahim Aissani
JMJeremy Martinson
Jeremy Martinson
CRCharles S Rabkin
Charles S Rabkin
Background: Cytokine stimulation of B-cell proliferation may be an important causative mechanism for acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). The Epstein–Barr virus (EBV) may be a co-factor, particularly for primary central nervous system (CNS) tumors, which are uniformly EBV-positive in the setting of AIDS. Thus, we examined associations of genetic variation in IL10 and related cytokine-signaling molecules (IL10RA, CXCL12, IL13, IL4, IL4R, CCL5 and BCL6) with AIDS-related NHL risk and evaluated differences between primary CNS and systemic tumors. Patients and materials: We compared 160 Multicenter AIDS Cohort Study (MACS) participants with incident lymphomas, of which 90 followed another AIDS diagnosis, to HIV-1-seropositive controls matched on duration of lymphoma-free survival post-HIV-1 infection (N = 160) or post-AIDS diagnosis (N = 90). We fit conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: Carriage of at least one copy of the T allele for the IL10 rs1800871 (as compared to no copies) was associated with decreased AIDS-NHL risk specific to lymphomas arising from the CNS (CC vs. CT/TT: OR = 0.3; 95% CI 0.1, 0.7) but not systemically (CC vs. CT/TT: OR = 1.0; 95% CI 0.5, 1.9) (Pheterogeneity = 0.03). Carriage of two copies of the ‘low IL10’ haplotype rs1800896_A/rs1800871_T/rs1800872_A was associated with decreased lymphoma risk that varied by number of copies (Ptrend = 0.02). None of the ORs for the other studied polymorphisms was significantly different from 1.0. Conclusion: Excessive IL10 response to HIV-1 infection may be associated with increased risk of NHL, particularly in the CNS. IL10 dysregulation may be an important causative pathway for EBV-related lymphomagenesis.

1 December 2022 in Vaccine
Verified
Journal Article
Closed access
HWHui-Lee Wong
Hui-Lee Wong
ETEllen Tworkoski
Ellen Tworkoski
CZCindy Ke Zhou
Cindy Ke Zhou
MHMao Hu
Mao Hu
DTDeborah Thompson
Deborah Thompson
SASteven A. Anderson
Steven A. Anderson

10 July 2011 in Cancer Science
Verified
Journal Article
Open access
PDF file
HWHui‐Lee Wong
Hui‐Lee Wong
CRCharles S. Rabkin
Charles S. Rabkin
XSXiao‐Ou Shu
Xiao‐Ou Shu
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
QCQiuyin Cai
Qiuyin Cai
WCWong‐Ho Chow
Wong‐Ho Chow
Although control of the host cytokine network is known to influence gastric cancer susceptibility, the specific inflammatory responses in gastric carcinogenesis remain unclear. We prospectively examined the relationships between gastric cancer risk and plasma levels of interleukin (IL)‐1β, IL‐6, IL‐8 and tumor necrosis factor (TNF)‐α in a nested case control study within The Shanghai Women’s Health Study. Two controls were matched to each case on the basis of age, menopausal status, and sample collection parameters. The associations between gastric cancer risk and tertiles of cytokine levels were estimated by odds ratios (OR) and 95% confidence intervals (CI) from conditional logistic regression, adjusting for education. During a median follow‐up period of 4 years (range 0.1–8 years), 141 women developed gastric cancer and were matched to 282 cancer‐free study participants. Elevated levels of plasma IL‐6 were associated with an increased risk of gastric cancer (Ptrend = 0.04). Risk increased 70% (OR = 1.7; 95% CI 1.0, 3.0) for women in the highest tertile (>4 pg/mL) of IL‐6 compared with those in the lowest tertile (<1.8 pg/mL). The association between gastric cancer risk and IL‐6 was stronger after 4 years of follow‐up (OR = 2.6 [95% CI 1.0, 6.7] for highest versus lowest tertile) compared with an OR of 1.4 (95% CI 0.7, 2.9) for those diagnosed within 1–4 years of follow‐up. No associations were observed with the other pro‐inflammatory cytokines examined, namely IL‐1β, IL‐8, and TNF‐α. Systemic plasma IL‐6 levels may inform long‐term gastric cancer risk. This novel finding awaits confirmation in future studies with sequential plasma collection. (Cancer Sci 2011; 102: 1911–1915)

27 September 2022 in Vaccine
Verified
Journal Article
Closed access
PLPatricia C. Lloyd
Patricia C. Lloyd
MHMao Hu
Mao Hu
HWHui-Lee Wong
Hui-Lee Wong
ASAzadeh Shoaibi
Azadeh Shoaibi
CZCindy Ke Zhou
Cindy Ke Zhou
SASteven A. Anderson
Steven A. Anderson


1 March 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
PSPatrick Saunders-Hastings
Patrick Saunders-Hastings
CZCindy Ke Zhou
Cindy Ke Zhou
SHShayan Hobbi
Shayan Hobbi
EBEva Boyd
Eva Boyd
PLPatricia C Lloyd
Patricia C Lloyd
ASAzadeh Shoaibi
Azadeh Shoaibi
COVID-19 infections have contributed to substantial increases in hospitalizations. This study describes demographics, baseline clinical characteristics and treatments, and clinical outcomes among U.S. patients admitted to hospitals with COVID-19 during the prevaccine phase of the pandemic. A total of 20,446 hospitalized patients with a positive COVID-19 nucleic acid amplification test were identified from three large electronic health record databases during 5 February–30 November 2020 (Academic Health System: n = 4504; Explorys; n = 7492; OneFlorida: n = 8450). Over 90% of patients were ≥30 years of age, with an even distribution between sexes. At least one comorbidity was recorded in 84.6–96.1% of patients; cardiovascular and respiratory conditions (28.8–50.3%) and diabetes (25.6–44.4%) were most common. Anticoagulants were the most frequently reported medications on or up to 28 days after admission (44.5–81.7%). Remdesivir was administered to 14.1–24.6% of patients and increased over time. Patients exhibited higher COVID-19 severity 14 days following admission than the 14 days prior to and on admission. The length of in-patient hospital stay ranged from a median of 4 to 6 days, and over 85% of patients were discharged alive. These results promote understanding of the clinical characteristics and hospital-resource utilization associated with hospitalized COVID-19 over time.